NASDAQ: BLTEBelite Bio Inc Stock
$28.02+1.01 (+3.74%)
Updated Mar 27, 2023
BLTE Price
$28.02
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$8.80
52 Week High
$44.70
P/E
-27.74x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.11
Operating Cash Flow
-$7M
Beta
-0.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BLTE Overview
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The company's pipeline of therapies is built on its RBP4 (Retinol Binding Protein 4) IP portfolio. Belite Bio is focused on meeting the unmet needs of patients suffering from blindness, liver disease, and diabetes. The company operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio was founded in 2016 and is based in San Diego, CA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BLTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLTE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLTE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BLTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BLTE due diligence checks available for Premium users.
Be the first to know about important BLTE news, forecast changes, insider trades & much more!
BLTE News
Valuation
BLTE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-27.74x
Industry
18.55x
Market
21.44x
BLTE's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BLTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.3M
Liabilities
$1.6M
Debt to equity
-0.11
BLTE's short-term assets ($17.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLTE's short-term assets ($17.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLTE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BLTE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Belite Bio Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.